Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

But for metastatic HER2 low cancer, there were few additional options, until clinical trials showed Enhertu kept the cancer at bay better than other treatments.

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab deruxtecan) plus rilvegostomig or pembrolizumab versus platinum-based ...

The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

More on AZN’s Datroway Datroway is the second antibody-drug conjugate (ADC) drug developed under the AstraZeneca-Daiichi partnership, the first being the blockbuster Enhertu.